KRAS and acute myeloid leukemia: Activating point mutations in KRAS are among the most prevalent genetic alterations in cancer, with highest incidences specific for certain epithelial (e.g., lung, pancreatic, and colorectal) and hematological (e.g., acute myeloid leukemia and multiple myeloma) malignancies (Prior et al, 2012).